Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Integrative multi-omics analysis reveals CXCL10-driven inflammation and TREM2 + macrophage-plasma cell survival niche as hallmarks of late-stage rheumatoid arthritis
by
Liu, Mengxia
, Peng, Yilin
, Li, Jianbin
, Wu, Rui
in
Biomarkers
/ Biopsy
/ C-reactive protein
/ Cells
/ CXCL10
/ Disease
/ Gene expression
/ Genomes
/ Histopathology
/ Immunohistochemistry
/ Inflammation
/ Machine learning
/ Macrophages
/ Medicine
/ Medicine & Public Health
/ Orthopedics
/ Patients
/ Plasma
/ Rheumatoid arthritis
/ Rheumatology
/ Single-cell RNA sequencing
/ Treatment resistance
/ TREM2
/ X-rays
2026
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Integrative multi-omics analysis reveals CXCL10-driven inflammation and TREM2 + macrophage-plasma cell survival niche as hallmarks of late-stage rheumatoid arthritis
by
Liu, Mengxia
, Peng, Yilin
, Li, Jianbin
, Wu, Rui
in
Biomarkers
/ Biopsy
/ C-reactive protein
/ Cells
/ CXCL10
/ Disease
/ Gene expression
/ Genomes
/ Histopathology
/ Immunohistochemistry
/ Inflammation
/ Machine learning
/ Macrophages
/ Medicine
/ Medicine & Public Health
/ Orthopedics
/ Patients
/ Plasma
/ Rheumatoid arthritis
/ Rheumatology
/ Single-cell RNA sequencing
/ Treatment resistance
/ TREM2
/ X-rays
2026
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Integrative multi-omics analysis reveals CXCL10-driven inflammation and TREM2 + macrophage-plasma cell survival niche as hallmarks of late-stage rheumatoid arthritis
by
Liu, Mengxia
, Peng, Yilin
, Li, Jianbin
, Wu, Rui
in
Biomarkers
/ Biopsy
/ C-reactive protein
/ Cells
/ CXCL10
/ Disease
/ Gene expression
/ Genomes
/ Histopathology
/ Immunohistochemistry
/ Inflammation
/ Machine learning
/ Macrophages
/ Medicine
/ Medicine & Public Health
/ Orthopedics
/ Patients
/ Plasma
/ Rheumatoid arthritis
/ Rheumatology
/ Single-cell RNA sequencing
/ Treatment resistance
/ TREM2
/ X-rays
2026
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Integrative multi-omics analysis reveals CXCL10-driven inflammation and TREM2 + macrophage-plasma cell survival niche as hallmarks of late-stage rheumatoid arthritis
Journal Article
Integrative multi-omics analysis reveals CXCL10-driven inflammation and TREM2 + macrophage-plasma cell survival niche as hallmarks of late-stage rheumatoid arthritis
2026
Request Book From Autostore
and Choose the Collection Method
Overview
Background
Rheumatoid arthritis (RA) is characterized by persistent synovial inflammation, yet the molecular mechanisms distinguishing early from late-stage disease remain incompletely elucidated. Identifying stage-specific biomarkers and pathogenic cellular interactions is crucial for precision medicine.
Objective
To comprehensively characterize the transcriptomic landscape and cellular composition of early versus late RA synovium, identify diagnostic biomarkers, and elucidate key pathogenic cell–cell interactions driving disease chronicity.
Methods
Synovial tissues from 51 RA patients (13 early, 38 late-stage) were analyzed using histopathology, immunohistochemistry, bulk RNA sequencing (
n
= 19),and single-cell RNA sequencing (scRNA-seq,
n
= 6; 3 Early RA vs. 3 Late-stage RA).Machine learning algorithms (LASSO, SVM-RFE, random forest) were employed to identify diagnostic biomarkers. An artificial neural network (ANN) model was constructed and validated. Cell–cell communication analysis was performed using CellChat.
Results
Histopathological analysis revealed significantly increased infiltration of macrophages (CD68 +) and plasma cells (CD138 +) in late-stage RA (
P
< 0.05). RNA sequencing identified 87 differentially expressed genes, with interferon-stimulated genes significantly upregulated. Integrated machine learning identified a minimal three-gene signature (CXCL10, ISG15, IFIH1) as a promising candidate model for RA staging. The three-gene ANN model showed excellent diagnostic performance (AUC = 0.922). Notably, CXCL10 emerged as the most critical component, demonstrating potentially high classification accuracy in this cohort (AUC = 0.767) and standing as the sole independent predictor in multivariable analysis (OR = 7.271,
P
= 0.022). CXCL10 high expression was strongly associated with M1 macrophage infiltration (
r
= 0.446,
P
= 0.005) and enriched in chemokine and JAK-STAT pathways. scRNA-seq revealed macrophages as the primary source of CXCL10, with upstream stimulation from CD8 + T cells via the IFN-γ-CXCL10-CXCR3 axis. Critically, we identified an expanded TREM2 + macrophage subset in late RA, which highly expressed APRIL (TNFSF13) and expanded in parallel with plasma cells expressing APRIL receptors (BCMA + /TACI +). This TREM2 + macrophage-plasma cell niche may represent a potential pathogenic circuit that could contribute to autoimmune chronicity.
Conclusions
Late-stage RA appears to be characterized by a CXCL10-driven inflammatory signature and an expanded TREM2 + macrophage-plasma cell survival niche. CXCL10 represents a promising candidate biomarker for disease staging that may have mechanistic links to pathogenesis. The IFN-γ-CXCL10-CXCR3 axis and the APRIL-BCMA/TACI pathway may constitute potential therapeutic targets for refractory RA.
MBRLCatalogueRelatedBooks
This website uses cookies to ensure you get the best experience on our website.